Track ProQR Therapeutics N.V. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

ProQR Therapeutics N.V. PRQR Open ProQR Therapeutics N.V. in new tab

1.71 USD
EPS
-0.46
P/B
2.80
ROE
-61.17
Beta
0.09
Target Price
8.88 USD
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateApril 30, 2026
EPS-0.46
Book Value0.54
Price to Book2.80
Debt/Equity32.33
% Insiders18.096%
Growth
Revenue Growth0.06%
Estimates
Forward P/E-3.21
Forward EPS-0.47
Target Mean Price8.88

DCF Valuation

Tweak assumptions to recompute fair value for ProQR Therapeutics N.V. (PRQR)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

ProQR Therapeutics N.V. Logo ProQR Therapeutics N.V. Analysis (PRQR)

Netherlands Health Care Official Website Stock

Is ProQR Therapeutics N.V. a good investment? ProQR Therapeutics N.V. (PRQR) is currently trading at 1.71 USD. Market analysts have a consensus price target of 8.88 USD. This suggests a potential upside from current levels.

Earnings Schedule: ProQR Therapeutics N.V. is expected to release its next earnings report on April 30, 2026. The market consensus estimate for Forward EPS is -0.47.

Investor FAQ

Does ProQR Therapeutics N.V. pay a dividend?

No, it does not currently pay a dividend.

What asset class is ProQR Therapeutics N.V.?

ProQR Therapeutics N.V. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be April 30, 2026. The company currently has a trailing EPS of -0.46.

Company Profile

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Exchange Ticker
NMS (United States) PRQR

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion